• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

奈立膦酸盐的临床发展：新应用的潜力。

Clinical development of neridronate: potential for new applications.

机构信息

Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy.

出版信息

Ther Clin Risk Manag. 2013;9:139-47. doi: 10.2147/TCRM.S35788. Epub 2013 Apr 3.

DOI:10.2147/TCRM.S35788
PMID:23589692
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3622395/
Abstract

Neridronate is an aminobisphosphonate, licensed in Italy for the treatment of osteogenesis imperfecta (OI) and Paget's disease of bone (PDB). A characteristic property of neridronate is that it can be administered both intravenously and intramuscularly, providing a useful system for administration in homecare. In this review, we discuss the latest clinical results of neridronate administration in OI and PDB, as well as in osteoporosis and other conditions. We will focus in particular on the latest evidence of the effect of neridronate on treatment of complex regional pain syndrome type I.

摘要

奈立膦酸盐是一种氨基双膦酸盐，在意大利被批准用于治疗成骨不全症（OI）和骨 paget 病（PDB）。奈立膦酸盐的一个特征性质是它既可以静脉内给药也可以肌内给药，为家庭护理中的给药提供了一种有用的系统。在这篇综述中，我们讨论了奈立膦酸盐在 OI 和 PDB 以及骨质疏松症和其他疾病中的最新临床结果。我们将特别关注奈立膦酸盐治疗 I 型复杂性区域疼痛综合征的最新疗效证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b04/3622395/3a2cc2a8a837/tcrm-9-139f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b04/3622395/8de3d75a56f4/tcrm-9-139f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b04/3622395/5a31af7e0aeb/tcrm-9-139f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b04/3622395/86f1843ab4f5/tcrm-9-139f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b04/3622395/3a2cc2a8a837/tcrm-9-139f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b04/3622395/8de3d75a56f4/tcrm-9-139f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b04/3622395/5a31af7e0aeb/tcrm-9-139f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b04/3622395/86f1843ab4f5/tcrm-9-139f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b04/3622395/3a2cc2a8a837/tcrm-9-139f4.jpg

相似文献

1
Clinical development of neridronate: potential for new applications.奈立膦酸盐的临床发展：新应用的潜力。
Ther Clin Risk Manag. 2013;9:139-47. doi: 10.2147/TCRM.S35788. Epub 2013 Apr 3.
2
Efficacy of teriparatide neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study.特立帕肽与奈立膦酸治疗Ⅰ型成骨不全症成人患者的疗效：一项前瞻性随机国际临床研究。
Clin Cases Miner Bone Metab. 2017 May-Aug;14(2):153-156. doi: 10.11138/ccmbm/2017.14.1.153. Epub 2017 Oct 25.
3
The Rationale for Using Neridronate in Musculoskeletal Disorders: From Metabolic Bone Diseases to Musculoskeletal Pain.用于肌肉骨骼疾病的奈立膦酸盐的原理：从代谢性骨病到肌肉骨骼疼痛。
Int J Mol Sci. 2022 Jun 22;23(13):6921. doi: 10.3390/ijms23136921.
4
Intramuscular neridronate in patients with rheumatoid arthritis using corticosteroids: evaluation of treatment adherence in a randomized, open-label comparison with other bisphosphonates.类风湿关节炎患者使用皮质类固醇时肌内注射奈立膦酸盐：与其他双膦酸盐进行随机、开放标签比较的治疗依从性评估
Acta Biomed. 2013 Jun 1;84(1):23-9.
5
Intravenous neridronate in adults with osteogenesis imperfecta.静脉注射奈立膦酸治疗成骨不全症成人患者。
J Bone Miner Res. 2003 Jan;18(1):126-30. doi: 10.1359/jbmr.2003.18.1.126.
6
Hypocalcemia following Neridronate Administration in Pediatric Patients with Osteogenesis Imperfecta: A Prospective Observational Study.奈立膦酸治疗成骨不全患儿后的低钙血症：一项前瞻性观察研究。
J Pediatr Genet. 2020 Jun;9(2):93-100. doi: 10.1055/s-0039-1700972. Epub 2020 Jan 6.
7
Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α.双膦酸盐治疗与未治疗的成骨不全儿童的骨重塑受损：DKK1、RANKL和TNF-α的作用
Osteoporos Int. 2016 Jul;27(7):2355-2365. doi: 10.1007/s00198-016-3501-2. Epub 2016 Feb 8.
8
Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.静脉注射奈立膦酸治疗成骨不全患儿：一项随机对照研究。
J Bone Miner Res. 2005 May;20(5):758-63. doi: 10.1359/JBMR.041232. Epub 2004 Dec 20.
9
Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw.接受奈立膦酸盐治疗的成骨不全症儿童和青少年没有任何颌骨骨坏死的证据。
J Bone Miner Metab. 2012 Jul;30(4):434-8. doi: 10.1007/s00774-011-0331-3. Epub 2011 Nov 8.
10
Long-term Effects of Neridronate in Adults with Osteogenesis Imperfecta: An Observational Three-Year Italian Study.奈立膦酸对成骨不全成人患者的长期影响：一项为期三年的意大利观察性研究。
Calcif Tissue Int. 2017 Apr;100(4):341-347. doi: 10.1007/s00223-017-0236-9. Epub 2017 Jan 27.

引用本文的文献

1
Medication-related osteonecrosis of the jaw (MRONJ): a review of pathogenesis hypothesis and therapy strategies.药物相关性下颌骨坏死（MRONJ）：发病机制假说和治疗策略的综述。
Arch Toxicol. 2024 Mar;98(3):689-708. doi: 10.1007/s00204-023-03653-7. Epub 2023 Dec 28.
2
Clinical Response to Treatment with Teriparatide in an Adolescent with Osteoporosis-Pseudoglioma Syndrome (OPPG): A Case Report.一名患有骨质疏松-假性胶质瘤综合征（OPPG）的青少年对特立帕肽治疗的临床反应：病例报告
Int J Endocrinol Metab. 2022 Apr 27;20(2):e121031. doi: 10.5812/ijem-121031. eCollection 2022 Apr.
3
Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.

本文引用的文献

1
Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study.用奈立膦酸盐治疗 I 型复杂性区域疼痛综合征：一项随机、双盲、安慰剂对照研究。
Rheumatology (Oxford). 2013 Mar;52(3):534-42. doi: 10.1093/rheumatology/kes312. Epub 2012 Nov 30.
2
Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.地舒单抗治疗绝经后骨质疏松症与骨硬化蛋白和 DKK1。
J Bone Miner Res. 2012 Nov;27(11):2259-63. doi: 10.1002/jbmr.1681.
3
Bisphosphonates in multiple myeloma: a network meta-analysis.
奈立膦酸盐治疗杜氏肌营养不良症患者骨丢失的疗效：一项初步研究的结果。
Adv Ther. 2022 Jul;39(7):3308-3315. doi: 10.1007/s12325-022-02179-1. Epub 2022 May 25.
4
A Review Into the Effects of Pamidronic Acid and Zoledronic Acid on the Oral Mucosa in Medication-Related Osteonecrosis of the Jaw.帕米膦酸和唑来膦酸对颌骨药物相关性骨坏死口腔黏膜影响的综述
Front Oral Health. 2022 Feb 9;2:822411. doi: 10.3389/froh.2021.822411. eCollection 2021.
5
Biocompatible coated magnetosome minerals with various organization and cellular interaction properties induce cytotoxicity towards RG-2 and GL-261 glioma cells in the presence of an alternating magnetic field.具有各种组织和细胞相互作用特性的生物相容性包被磁小体矿物质，在交变磁场存在的情况下，会对RG-2和GL-261胶质瘤细胞诱导细胞毒性。
J Nanobiotechnology. 2017 Oct 17;15(1):74. doi: 10.1186/s12951-017-0293-2.
6
Clinical and biochemical response to neridronate treatment in a patient with osteoporosis-pseudoglioma syndrome (OPPG).骨质疏松-假性脑肿瘤综合征（OPPG）患者应用奈立膦酸钠治疗的临床和生化反应。
Osteoporos Int. 2017 Nov;28(11):3277-3280. doi: 10.1007/s00198-017-4214-x. Epub 2017 Sep 2.
7
New insights into human farnesyl pyrophosphate synthase inhibition by second-generation bisphosphonate drugs.第二代双膦酸盐药物对人法尼基焦磷酸合酶抑制作用的新见解。
J Comput Aided Mol Des. 2017 Jul;31(7):675-688. doi: 10.1007/s10822-017-0034-5. Epub 2017 Jun 19.
8
Multiple diaphyseal sclerosis (Ribbing disease): what about neridronate?多发性骨干硬化症（里宾病）：奈立膦酸怎么样？
Osteoporos Int. 2016 Oct;27(10):3127-31. doi: 10.1007/s00198-016-3604-9. Epub 2016 Apr 22.
9
Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis.用于快速检测动脉粥样硬化的微波驱动氧化铁纳米颗粒的合成
J Vis Exp. 2016 Mar 22(109):53472. doi: 10.3791/53472.
10
Management of patients with complex regional pain syndrome type I.Ⅰ型复杂性区域疼痛综合征患者的管理
Osteoporos Int. 2016 Aug;27(8):2423-31. doi: 10.1007/s00198-016-3531-9. Epub 2016 Feb 29.
双膦酸盐类药物治疗多发性骨髓瘤：一项网状Meta分析
Cochrane Database Syst Rev. 2012 May 16(5):CD003188. doi: 10.1002/14651858.CD003188.pub3.
4
Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study.奈立膦酸盐可改善β-地中海贫血伴骨质疏松症患者的骨密度并减轻背痛：来自一项 2 期、随机、平行臂、开放性研究的结果。
Br J Haematol. 2012 Jul;158(2):274-282. doi: 10.1111/j.1365-2141.2012.09152.x. Epub 2012 May 10.
5
Progress in the treatment of bone metastases in cancer patients.癌症患者骨转移治疗进展。
Expert Opin Investig Drugs. 2012 Jun;21(6):785-95. doi: 10.1517/13543784.2012.679928. Epub 2012 Apr 16.
6
Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin.双磷酸盐治疗绝经后骨质疏松症与血清硬化素呈剂量依赖性增加有关。
Bone. 2012 Mar;50(3):739-42. doi: 10.1016/j.bone.2011.11.028. Epub 2011 Dec 10.
7
Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw.接受奈立膦酸盐治疗的成骨不全症儿童和青少年没有任何颌骨骨坏死的证据。
J Bone Miner Metab. 2012 Jul;30(4):434-8. doi: 10.1007/s00774-011-0331-3. Epub 2011 Nov 8.
8
Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta.成骨不全症患儿用奈立膦酸盐或帕米膦酸盐治疗期间的脊柱重塑。
Horm Res Paediatr. 2011;76(5):321-7. doi: 10.1159/000331128. Epub 2011 Sep 27.
9
Long-term effects of neridronate and its discontinuation in patients with primary hyperparathyroidism.原发性甲状旁腺功能亢进患者使用奈立膦酸及其停药的长期疗效。
Calcif Tissue Int. 2011 Jul;89(1):21-8. doi: 10.1007/s00223-011-9489-x. Epub 2011 May 13.
10
The relationship between the chemistry and biological activity of the bisphosphonates.双膦酸盐的化学和生物学活性之间的关系。
Bone. 2011 Jul;49(1):20-33. doi: 10.1016/j.bone.2011.03.774. Epub 2011 Apr 9.